Clinical Safety/Tolerability of HF0220 and Its Effect on Biochemical Markers Relevant to Patients With a Diagnosis of Mild to Moderate Alzheimer' Disease
Phase of Trial: Phase II
Latest Information Update: 01 Jun 2011
At a glance
- Drugs HF 0220 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Biomarker
- Sponsors Hunter-Fleming
- 23 Oct 2008 Results reported in a Newron media release.
- 20 Aug 2008 Status changed from recruiting to completed, as reported on ClinicalTrials.gov.
- 02 Nov 2006 New trial record.